Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

We previously evaluated Wilms’ tumor gene 1 (WT1) peptide vaccination in a large number of patients with leukemia or solid tumors and have reported that HLA‐A*24:02 restricted, 9‐mer WT1‐235 peptide (CYTWNQMNL) vaccine induces cellular immune responses and elicits WT1‐235‐specific cytotoxic T lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Oji, Yusuke, Hashimoto, Naoya, Tsuboi, Akihiro, Murakami, Yui, Iwai, Miki, Kagawa, Naoki, Chiba, Yasuyoshi, Izumoto, Shuichi, Elisseeva, Olga, Ichinohasama, Ryo, Sakamoto, Junichi, Morita, Satoshi, Nakajima, Hiroko, Takashima, Satoshi, Nakae, Yoshiki, Nakata, Jun, Kawakami, Manabu, Nishida, Sumiyuki, Hosen, Naoki, Fujiki, Fumihiro, Morimoto, Soyoko, Adachi, Mayuko, Iwamoto, Masahiro, Oka, Yoshihiro, Yoshimine, Toshiki, Sugiyama, Haruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Tumor Immunology and Microenvironment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089562/
https://www.ncbi.nlm.nih.gov/pubmed/27170523
http://dx.doi.org/10.1002/ijc.30182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089562/
https://www.ncbi.nlm.nih.gov/pubmed/27170523
http://dx.doi.org/10.1002/ijc.30182

Ejemplares similares